Basic Information
Tacforius
Regulatory Information
EMEA/H/C/004435
December 8, 2017
October 12, 2017
10
December 11, 2024
Company Information
Netherlands
Swensweg 5 2031 GA Haarlem
Teva Pharma B.V.
Drug Classification
Active Substances Detail
tacrolimus monohydrate
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Tacforius. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Tacforius. For practical information about using Tacforius, patients should read the package leaflet or contact their doctor or pharmacist.